238803
Cdk2 Inhibitor III
The Cdk2 Inhibitor III, also referenced under CAS 199986-75-9, controls the biological activity of Cdk2. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
别名:
Cdk2 Inhibitor III, 2( bis-(Hydroxyethyl)amino)-6-(4-methoxybenzylamino)-9-isopropyl-purine, CVT-313, 2(bis-(Hydroxyethyl)amino)-6-(4-methoxybenzylamino)-9-isopropyl-purine, CVT-313
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
质量水平
方案
≥98% (HPLC)
表单
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
protect from light
颜色
white
溶解性
DMSO: 10 mg/mL
运输
ambient
储存温度
2-8°C
SMILES字符串
[n]1(c2nc(nc(c2nc1)NCc3ccc(cc3)OC)N(CCO)CCO)C(C)C
InChI
1S/C20H28N6O3/c1-14(2)26-13-22-17-18(21-12-15-4-6-16(29-3)7-5-15)23-20(24-19(17)26)25(8-10-27)9-11-28/h4-7,13-14,27-28H,8-12H2,1-3H3,(H,21,23,24)
InChI key
NQVIIUBWMBHLOZ-UHFFFAOYSA-N
一般描述
A cell-permeable purine analog that acts as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk2 (IC50 = 0.5 µM for Cdk2/A and Cdk2/E; 4.2 µM for Cdk1/B; 215 µM for Cdk4/D1). Inhibits other kinases only at much higher concentrations (IC50 >1.25 mM for MAPK, PKA, and PKC). Shown to induce tumor cells growth arrest (IC50 = ~1.25-20 µM) in vitro and prevent neointima formation in vivo.
A cell-permeable purine analog that acts as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk2 (IC50 = 0.5 µM for Cdk2/A and Cdk2/E; 4.2 µM for Cdk1/B; 215 µM for Cdk4/D1). Inhibits other kinases only at much higher concentrations (IC50 >1.25 mM for MAPK, PKA, and PKC). Shown to induce tumor cells growth arrest (IC50 ~1.25-20 µM) in vitro and prevent neointima formation in vivo.
生化/生理作用
Cell permeable: yes
Primary Target
Cdk2/A, Cdk2/E
Cdk2/A, Cdk2/E
Product competes with ATP.
Reversible: yes
Target IC50: 0.5 µM for Cdk2/A and Cdk2/E; 4.2 µM for Cdk1/B; 215 µM for Cdk4/D1
包装
Packaged under inert gas
警告
Toxicity: Carcinogenic / Teratogenic (D)
重悬
Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他说明
Bhattacharjee, R.N., et al. 2001. Mol. Cell. Biol.21, 5417.
Brooks, E.E., et al. 1997. J. Biol. Chem.272, 29207.
Brooks, E.E., et al. 1997. J. Biol. Chem.272, 29207.
法律信息
Sold under license of U.S. Patents 6,617,331 and 6,803,371.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
储存分类代码
11 - Combustible Solids
WGK
WGK 1
Haitao Liu et al.
Journal of virology, 95(12) (2021-04-02)
Hepatitis B virus (HBV) capsid or core protein (HBc) consists of an N-terminal domain (NTD) and a C-terminal domain (CTD) connected by a short linker peptide. Dynamic phosphorylation and dephosphorylation of HBc regulate its multiple functions in capsid assembly and
Sungsoo Kim et al.
Scientific reports, 12(1), 16810-16810 (2022-10-08)
External signaling controls cell-cycle entry until cells irreversibly commit to the cell cycle to ensure faithful DNA replication. This process is tightly regulated by cyclin-dependent kinases (CDKs) and the retinoblastoma protein (Rb). Here, using live-cell sensors for CDK4/6 and CDK2
Tom Kaufman et al.
Nature communications, 13(1), 2725-2725 (2022-05-19)
While multiplexing samples using DNA barcoding revolutionized the pace of biomedical discovery, multiplexing of live imaging-based applications has been limited by the number of fluorescent proteins that can be deconvoluted using common microscopy equipment. To address this limitation, we develop
Arnav Moudgil et al.
Cell, 182(4), 992-1008 (2020-07-28)
Cellular heterogeneity confounds in situ assays of transcription factor (TF) binding. Single-cell RNA sequencing (scRNA-seq) deconvolves cell types from gene expression, but no technology links cell identity to TF binding sites (TFBS) in those cell types. We present self-reporting transposons
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门